• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Preventive Efficacy of Oxidized Dextran and Pathomorphological Processes in Mouse Lungs in Avian Influenza A/H5N1

tetano

Editor, Senior Moderator
Bull Exp Biol Med. 2011 Apr;150(6):707-10.
Preventive Efficacy of Oxidized Dextran and Pathomorphological Processes in Mouse Lungs in Avian Influenza A/H5N1.
[Article in English, Russian]
Potapova OV, Shkurupiy VA, Sharkova TV, Troitskiy AV, Lusgina NG, Shestopalov AM.
Source

Research Center of Clinical and Experimental Medicine, Siberian Division of the Russian Academy of Medical Sciences, Novosibirsk, Russia. potapova@soramn.ru.
Abstract

Oxidized dextran (60 kDa) exerts a pronounced preventive effect in laboratory mice infected with avian influenza subtype H5N1 A/Goose/Krasnoozerskoye/627/05 virus, which manifested in a significant increase in mouse lifetime (by 24.4%) and mortality rate (3.3-fold). This was probably related to significant alleviation of pathological changes in the lungs and severity of hemodynamic and inflammatory complications and early fibrosis.

PMID:
22235423
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/22235423
 
Back
Top Bottom